Questions
Ipamorelin, answered.
Direct answers to the questions people actually ask about ipamorelin — approval, legality, sport status, mechanism, and timing — each cited where it makes a quantitative claim.
Is ipamorelin FDA approved?
No. Ipamorelin has never been approved by the FDA as a drug for any indication. Its only Phase 2 trial, for postoperative ileus, missed its primary endpoint, and no Phase 3 followed [3]. In 2024 the FDA also tightened its compounding status, reviewing it at the October 29, 2024 PCAC meeting [7]. It is marketed only as a research chemical.
Is ipamorelin legal?
Ipamorelin is not an approved drug, and it is sold as a research chemical "for research use only," which sits in a separate regulatory lane from approved medicines [7]. It is not a controlled substance in the narcotics sense, but it has no approved human use. A 2020 andrology review discusses the gap between how this class is marketed and what is actually approved [7]. Sport rules are separate — see the WADA answer below.
Is ipamorelin banned by WADA?
Yes. Ipamorelin is prohibited in sport at all times under the WADA Prohibited List, category S2, as a growth hormone secretagogue [9]. Accredited laboratories can detect it in urine; a validated LC-MS method identified ipamorelin alongside seven other GHRPs with detection limits of 0.2–1 ng/mL [9]. Any athlete subject to testing should treat it as a banned substance.
Why did the FDA restrict ipamorelin compounding?
In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list (following nominator withdrawal in September 2024) and reviewed it at the October 29, 2024 PCAC meeting [7]. Section 503A governs which bulk substances compounding pharmacies may use; ipamorelin is not an approved bulk substance for compounding, so the 2024 direction was toward restricting access, not expanding it [7].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and the first highly selective growth hormone secretagogue [1]. In its founding study it released GH potently in rat pituitary cells, rats, and swine (swine ED50 2.3 nmol/kg) without raising ACTH or cortisol even at more than 200x its GH-releasing dose [1]. It works at the ghrelin/GHS-R1a receptor and is not an approved drug.
What does ipamorelin do for you?
In studies, ipamorelin triggers a discrete pulse of growth hormone by activating the ghrelin receptor [1][2]. What it does in people for general use is largely uncharacterized: the only Phase 2 efficacy trial (postoperative ileus) missed its endpoint [3]. Community reports describe better sleep and recovery, but those are anecdotal, not clinical findings. It is not an approved therapy for any purpose.
What is ipamorelin peptide?
Ipamorelin peptide is the same compound: a wholly synthetic five-amino-acid peptide (formula C₃₈H₄₉N₉O₅) that selectively activates the ghrelin/GHS-R1a receptor to release growth hormone, without the cortisol and prolactin spillover of older GHRPs [1]. It is a research peptide, not an endogenous human hormone, and it is not approved as a drug anywhere.
What are the risks of ipamorelin?
The documented human safety database is tiny — one 7-day Phase 2 trial (n=114) and one acute PK study [2][3]. Mechanistic and class-level cautions include GH-axis effects on blood sugar and fluid balance, a class-level cardiotoxicity signal seen in a 28-day rat study of a related GHS-R1a agonist [6], and unverified purity of research-grade material. Long-term human safety is uncharacterized.
Does ipamorelin reduce belly fat?
There is no human trial showing ipamorelin reduces belly fat. In a 2024 ferret study, ipamorelin (1–3 mg/kg intraperitoneal) reduced chemotherapy-induced weight loss by about 24% — a different effect from fat loss [5]. In mice it actually raised fat-pad weight and leptin [14]. Community reports of a gradual leaner look are anecdotal and confounded by diet and training.
What are the downsides of ipamorelin?
Reported downsides (anecdotal) include facial flushing, tingling, water retention, increased appetite, lightheadedness, and injection-site irritation. Evidence-based concerns include a thin human safety file [2][3], a class-level cardiac signal in a 28-day rat study of a related agonist [6], and unverified material quality. The biggest downside is simply how little controlled human evidence exists.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product, so it was never "discontinued" in the usual sense. Its clinical development effectively ended when the only Phase 2 trial (postoperative ileus) missed its primary endpoint and no Phase 3 followed [3]. Separately, in 2024 the FDA tightened its compounding-pharmacy status, restricting one access route [7].
What does CJC-1295 and ipamorelin do?
Together they aim to raise growth hormone through two pathways: CJC-1295 (a long-acting GHRH analog) lifts the GHRH-pathway baseline, while ipamorelin (a GHRP) adds a ghrelin-receptor pulse [1][10]. The combination has no controlled human trial; its rationale rests on each agent's separate pharmacology, where CJC-1295 alone produced multi-day GH and IGF-1 elevation in healthy adults [10].
Does ipamorelin increase IGF-1?
Not consistently in short studies. In the rat bone-growth study, ipamorelin raised longitudinal bone growth dose-dependently but with no measurable change in total IGF-1 [4]. Sustained GH stimulation by GHRP-class peptides can elevate IGF-1 over longer protocols [10], but ipamorelin's own short-term rodent data did not always show an IGF-1 rise [4].
How does CJC-1295 ipamorelin work?
CJC-1295 binds the GHRH receptor to raise the baseline drive for GH, while ipamorelin binds the ghrelin/GHS-R1a receptor to add a discrete GH pulse [1][10]. Stimulating both pathways can produce a larger combined GH release than either alone — a class-level principle shown for GHRH + GHRP pairs [10][11] — though the specific CJC-1295/ipamorelin pairing has not been tested in a controlled trial.
How much CJC-1295 ipamorelin should I take?
This site does not provide a human dose. No controlled human trial has tested the combination, so there is no evidence-based dosing for it [3]. For research context only: ipamorelin's human work used IV infusions and a 0.03 mg/kg IV trial dose [2][3]; CJC-1295's single-agent study used 30–60 µg/kg subcutaneously [10]. Subcutaneous stack regimens online have no peer-reviewed human basis.
Does CJC-1295 ipamorelin work?
The combination has never been tested as a combination in a controlled human trial for any outcome, so efficacy cannot be claimed from combination data [3]. Single-agent pharmacology exists: CJC-1295 produced 2- to 10-fold GH increases for 6+ days after one dose [10], and ipamorelin produces a discrete GH pulse [2]. "Works" remains unproven for the pairing itself.
How to reconstitute CJC-1295 ipamorelin 5mg?
As general research-handling context only: these peptides ship as lyophilized (freeze-dried) powder and are reconstituted with bacteriostatic water, kept refrigerated, and protected from heat and repeated freeze-thaw to limit degradation. This site does not provide a human preparation protocol — ipamorelin is not an approved medicine and no human dosing pathway is given here [2].
How long does ipamorelin stay in your system?
Ipamorelin's terminal half-life in healthy human volunteers is about 2 hours after intravenous dosing [2]. The growth-hormone pulse it triggers peaks near 40 minutes and is brief, not sustained [2]. For doping purposes, though, detection windows differ from half-life: accredited labs can identify ipamorelin and its metabolites in urine by validated LC-MS methods [9].
Does ipamorelin make you hungry?
It can. Ipamorelin activates the ghrelin receptor — the body's hunger-signal receptor — so increased appetite is an expected class effect [15]. Community reports describe more hunger in the hours after injection, generally milder than with GHRP-6. In mice, ipamorelin raised adiposity and leptin independent of GH [14]. A 2026 review notes appetite/metabolic signals among its preclinical effects [16].
Will I gain weight on ipamorelin?
There is no human trial answering this directly. In animals, ipamorelin raised body weight, fat-pad weight, and leptin in mice [14], and reduced chemotherapy-induced weight loss in ferrets [5]. Because it stimulates appetite via the ghrelin receptor [15], weight change could go either way depending on intake. Community accounts of body recomposition are anecdotal and confounded.
Does ipamorelin increase appetite?
Yes, as a class effect. Ghrelin-receptor agonists activate hypothalamic appetite centers and induce feeding [15], and ipamorelin specifically raised adiposity and leptin in mice [14]. A 2026 sports-medicine review groups ipamorelin among unapproved peptides with preclinical metabolic effects but scarce rigorous human safety data [16]. Reported appetite increases are typically described as milder than with older GHRPs.
What does ipamorelin peptide do?
Ipamorelin peptide selectively activates the ghrelin/GHS-R1a receptor on pituitary cells to release a discrete pulse of growth hormone, without raising cortisol or prolactin [1]. Downstream effects studied in animals include longitudinal bone growth [4] and effects on body composition [14]. Its human efficacy is unproven — the only Phase 2 trial missed its endpoint [3] — and it is not an approved drug.